Sign in

You're signed outSign in or to get full access.

Ronen Rosenbloom

Director at N2OFF
Board

About Ronen Rosenbloom

Independent director of N2OFF, Inc. since August 2020; age 53. An independent lawyer specializing in white-collar offenses, he founded and has run his own law firm since 2004. Education: LL.B., Ono Academic College (Israeli branch of University of Manchester). External public board roles include Xylo Technologies Ltd. (Nasdaq: XYLO) since Sept 2018 and ScoutCam Inc. (OTC: SCTC) since Dec 2019 .

Past Roles

OrganizationRoleTenureCommittees/Impact
Israel Bar Association – Money Laundering Prohibition CommitteeChairmanNov 2015–Dec 2019Led policy oversight on AML; relevant to audit/controls
Tel Aviv District – Prohibition of Money Laundering CommitteeChairmanNov 2015–Dec 2019Regional AML governance leadership

External Roles

OrganizationRoleTenureCommittees/Impact
Xylo Technologies Ltd. (Nasdaq: XYLO)DirectorSince Sept 2018Technology exposure; board oversight experience
ScoutCam Inc. (OTC: SCTC)DirectorSince Dec 2019Industrial/tech oversight experience

Board Governance

  • Independence: Board determined Rosenbloom is independent under Nasdaq rules (including for audit and compensation committee service) .
  • Committee assignments:
    • Audit Committee: Member; committee met 5 times and acted 4 times by unanimous written consent in 2024; audit chair is Udi Kalifi; all members financially literate .
    • Nominating & Corporate Governance Committee: Chair; held no meetings and acted once by unanimous written consent in 2024 .
    • Compensation Committee: Member; held 1 meeting and acted 4 times by unanimous written consent in 2024; chair is Israel Berenstein .
  • Attendance: Board held 12 meetings in 2024; Rosenbloom attended all committee meetings and missed one board meeting; all other directors attended all meetings for their period of service .
  • Board leadership: Chair and CEO roles are separated (Chair: Amitay Weiss; CEO: David Palach) .
  • Anti-hedging: Company prohibits hedging/monetization transactions by directors and employees .

Fixed Compensation

Component (FY2024)Amount (USD)Detail
Cash fees$45,771 Director fees earned or paid in cash
Option awards$0 No option awards in 2024
Equity/other compensation$13,135 1,429 shares granted at $9.19 per share on Dec 23, 2024
Total$58,906 Sum of cash and equity/other

Note: The proxy footnote attributes the $13,135 “all other compensation” to restricted common stock (1,429 shares at $9.19) issued Dec 23, 2024 .

Performance Compensation

ItemStructureMetrics/Conditions
Annual director equity (FY2024)Restricted common stock grant (1,429 shares) No performance metrics disclosed for 2024 director equity
Proposed director equity (subject to vote)Aggregate 750,000 restricted shares to directors under 2022 Plan (allocation TBD), contingent on Plan amendment approval No performance conditions disclosed; proposal rationales include retention and alignment with stock price

2022 Share Incentive Plan amendment increases pool and permits various share-based awards; no director-specific performance metrics are described for the proposed grants .

Other Directorships & Interlocks

CompanyTypeRoleInterlock/Notes
Xylo Technologies Ltd. (Nasdaq: XYLO)PublicDirectorSeparate from N2OFF; no interlock disclosed in proxy
ScoutCam Inc. (OTC: SCTC)PublicDirectorSeparate from N2OFF; no interlock disclosed in proxy

Board-level related-party exposures at N2OFF involve Plantify, SciSparc, Pure Capital, and Solterra, with overlaps among other N2OFF directors; Rosenbloom is not named in these specific related transactions, but as audit committee member he participates in oversight of related person transactions .

Expertise & Qualifications

  • Legal expertise in white-collar offenses and AML policy leadership; LL.B. from Ono Academic College; practicing lawyer since 2004 .
  • Financial literacy for audit committee service confirmed by board; audit committee has an “financial expert” (Udi Kalifi) .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingNotes
Ronen Rosenbloom1,844 <1% (of 2,682,483 outstanding as of Oct 24, 2025) Includes right to acquire within 60 days, if any (none disclosed)
  • Anti-hedging policy in place; no pledging disclosed in proxy .
  • Director stock ownership guidelines: not disclosed in proxy .

Governance Assessment

  • Strengths:

    • Independent director with legal/AML background; chairs the nominating & governance committee; serves on audit and compensation committees .
    • Strong overall attendance (missed one board meeting) and active committee functioning; audit committee met 5 times in 2024 .
    • Anti-hedging policy and separation of Chair/CEO support governance rigor .
  • Risks/Considerations:

    • Low personal share ownership (<1%) limits “skin-in-the-game”; proposed large director share grants lack explicit performance conditions, raising alignment questions for investors focused on pay-for-performance .
    • Company has multiple related-party transactions (SciSparc, Pure Capital, Solterra, Plantify), requiring robust audit committee oversight; Rosenbloom’s audit role is central to mitigating related-party risks .
  • RED FLAGS:

    • Proposed aggregate grant of 750,000 restricted shares to directors without disclosed performance metrics (subject to Plan amendment) .
    • Numerous related-party transactions across affiliates and counterparties; continuous monitoring of audit committee processes necessary .

Say-on-Pay & Shareholder Feedback (Directors)

  • Advisory vote on granting shares to directors under the 2022 Plan (Proposal 3) at the Dec 16, 2025 annual meeting; non-binding and contingent on Plan amendment approval (Proposal 2) .

Clawback

  • Company adopted an SEC/Nasdaq-compliant clawback policy on Nov 12, 2023 (filed with 10-K on Mar 31, 2025) .

Insider Trades and Section 16

ItemDisclosure
Section 16(a) compliance (2024)Company states directors and officers timely filed required ownership reports in 2024
Form 4 detailsSpecific Form 4 transactions for Rosenbloom not detailed in proxy